Gate2Brain develops a proprietary peptide-based technology platform designed to enhance the delivery of therapeutics across biological barriers like the blood-brain barrier. This platform conjugates peptide shuttles to various cargoes, including small molecules and antibodies, to improve their biopharmaceutical properties in vitro and in vivo. The technology targets therapeutic areas where drug delivery across physiological barriers currently limits treatment efficacy.
Funding
$670K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many potential therapeutics for central nervous system (CNS) disorders, including pediatric brain tumors, fail because they cannot effectively cross the blood-brain barrier (BBB) to reach the brain in sufficient concentrations. This barrier, while protecting the brain, also prevents approximately 98% of candidate CNS drugs from reaching their target, limiting treatment options and efficacy. Current treatments for pediatric brain tumors such as diffuse intrinsic pontine glioma (DIPG) and pediatric glioblastoma (pGBM) are limited and often ineffective.
Solution
Gate2Brain (G2B) has developed a technology platform based on peptide shuttles that enhance the delivery of therapeutic cargoes across biological barriers, including the blood-brain barrier (BBB). These peptide shuttles are conjugated to various therapeutic modalities, such as small molecules, peptides, nanoparticles, proteins, and antibodies, to improve their biopharmaceutical properties and enable them to cross the BBB. G2B-002, the company's lead product, utilizes this technology to deliver an anticancer agent directly to pediatric brain tumors with an intact BBB, offering a new approach to treating these challenging conditions. The platform's modularity allows for potential application to a wide range of CNS diseases and therapeutic agents.
Target Audience
The primary target audience includes pharmaceutical companies and researchers developing therapeutics for CNS disorders, particularly those focusing on pediatric brain tumors with an intact blood-brain barrier.
Features
- Patented peptide-based technology platform for enhanced drug delivery across the blood-brain barrier
- Peptide shuttles capable of transporting small molecules, peptides, nanoparticles, proteins, and antibodies
- G2B-002, a lead product targeting pediatric brain tumors with an intact BBB
- Demonstrated preclinical efficacy against pediatric glioblastoma (pGBM) and diffuse intrinsic pontine glioma (DIPG)
- Potential scalability to other therapeutic cargoes and biological barriers
- Strong IP protection with six patents
- Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) for G2B-002